PUBLISHER: The Business Research Company | PRODUCT CODE: 1948357
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948357
A transcatheter valve repair system constitutes a minimally invasive procedure wherein a catheter is inserted through a small incision in the leg or chest and guided to the heart with the aid of imaging guidance. This approach is employed for treating patients with severe mitral regurgitation (grade 3+ or above) resulting from abnormal mitral valve leaflets and the surrounding region, especially when open-heart surgery is deemed excessively risky.
The primary products associated with the transcatheter valve repair system include transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter pulmonary valve replacement (TPVR), and transcatheter tricuspid valve replacement (TTVR). Transcatheter Aortic Valve Replacement (TAVR) specifically pertains to the replacement of an aortic valve afflicted with stenosis through a minimally invasive cardiac procedure. This method is applied to enhance blood flow and alleviate symptoms associated with aortic valve stenosis, such as fatigue, shortness of breath, fainting, and chest pain. The applications of transcatheter valve repair systems extend to aortic stenosis, mitral stenosis, tricuspid stenosis, and pulmonary stenosis, with utilization in hospitals, specialty clinics, ambulatory surgical centers, and other medical facilities.
Tariffs are influencing the transcatheter valve repair system market by increasing costs of imported catheter systems, implant components, imaging-compatible materials, and precision manufacturing tools. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported advanced devices, while Asia-Pacific faces higher production and distribution costs. These tariffs are elevating procedural expenses and slowing adoption in cost-sensitive settings. However, they are also promoting domestic device development, localized assembly, and innovation in scalable valve repair solutions.
The transcatheter valve repair system market research report is one of a series of new reports from The Business Research Company that provides transcatheter valve repair system market statistics, including transcatheter valve repair system industry global market size, regional shares, competitors with a transcatheter valve repair system market share, detailed transcatheter valve repair system market segments, market trends and opportunities, and any further data you may need to thrive in the transcatheter valve repair system industry. This transcatheter valve repair system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The transcatheter valve repair system market size has grown strongly in recent years. It will grow from $5.45 billion in 2025 to $5.93 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing prevalence of valvular heart diseases, growing elderly population, advancements in catheter navigation technologies, rising clinician experience with transcatheter interventions, expansion of cardiac specialty centers.
The transcatheter valve repair system market size is expected to see strong growth in the next few years. It will grow to $8.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing adoption of minimally invasive valve repair, rising demand for transcatheter mitral interventions, expansion of structural heart disease programs, growing innovation in multi-valve repair technologies, increasing focus on patient-specific treatment solutions. Major trends in the forecast period include increasing adoption of catheter-based valve repair procedures, rising demand for mitral valve repair systems, growing focus on high-risk surgical patients, expansion of multi-valve repair platforms, enhanced device navigability and control.
The growing global geriatric population is expected to drive growth in the transcatheter valve repair system market in the coming years. The geriatric population comprises individuals typically aged 65 and older. Transcatheter valve repair systems provide minimally invasive treatment options, which are particularly beneficial for older patients who may face higher surgical risks. For example, in October 2025, the World Health Organization (WHO), a Switzerland-based UN agency, projected that by 2030, one in six people globally will be aged 60 or older, with this population expected to double to 2.1 billion by 2050. Thus, the increasing geriatric population is fueling growth in the transcatheter valve repair system market.
Key companies in the transcatheter valve repair system market are focusing on innovations such as durability-enhanced transcatheter valves to improve long-term valve performance and optimize clinical outcomes for patients undergoing transcatheter valve replacement. A durability-enhanced transcatheter valve is a minimally invasive aortic replacement device made with advanced biomaterials to improve structural longevity and maintain effective valve function over time. For example, in May 2024, Edwards Lifesciences, a Switzerland-based provider of structural heart and critical care technologies, launched the SAPIEN 3 Ultra RESILIA valve. The device features proprietary anti-calcification tissue technology to reduce structural deterioration and support long-term performance, along with dry-tissue storage, demonstrating favorable early hemodynamic outcomes and highlighting its potential to enhance durability and expand treatment options for aortic valve disease patients.
In October 2024, Edwards Lifesciences, a US-based provider of structural heart therapies and transcatheter repair and replacement technologies, acquired Innovalve Bio Medical Ltd. for an undisclosed amount. Through this acquisition, Edwards aims to strengthen its transcatheter mitral and tricuspid therapy portfolio by enhancing its technology platform for next-generation mitral valve replacement and expanding its ability to address unmet needs in structural heart disease. Innovalve Bio Medical Ltd., based in Israel, provides early-stage transcatheter mitral valve replacement technologies designed to treat complex mitral valve pathologies.
Major companies operating in the transcatheter valve repair system market are Abbott Laboratories, Medtronic Plc., Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova Plc., Meril Life Sciences Pvt. Ltd., Cordis Corporation, MicroPort Scientific Corporation., Biotronik Pvt. Ltd, AtriCure Inc., OrbusNeich Medical Group Holdings Limited, Venus Medtech (Hangzhou) Inc., Dura LLC, HLT Medical Inc., Symetis SA, JenaValve Technology Inc., 4C Medical Technologies Inc., Cardiac Dimensions Inc., Valve Solutions Inc., Transcatheter Technologies GmbH, Evalve Corporation, Colibri Heart Valve LLC, Medtentia International Ltd., Coramaze Technologies Ltd., Neovasc Inc., Anteris Technologies Ltd.
North America was the largest region in the transcatheter valve repair systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transcatheter valve repair system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the transcatheter valve repair system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transcatheter valve repair systems market includes revenues earned by entities by providing mitraClip G4 system, NeoChord, harpon, and PaScal precision transcatheter. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transcatheter Valve Repair System Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses transcatheter valve repair system market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for transcatheter valve repair system ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transcatheter valve repair system market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.